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Given the relative modality of single-insult models to accurately reflect Alzheimer disease pathogenesis, based on studies on mitogenic and
oxidative stress signaling pathways, we proposed a two-hit hypothesis 2 years ago stating that both oxidative stress and mitogenic dysregulation
are necessary and sufficient to cause the disease and suggested that it may be a common mechanism for other neurodegenerative diseases as well
(X. Zhu, A.K. Raina, G. Perry, M.A. Smith, Alzheimer's disease: the two-hit hypothesis, Lancet Neurol. 3 (2004) 219–226.). Recent
developments in the field confirm some important predictions of the hypothesis and shed new lights on potential mechanisms regarding how
steady state may be achieved in sporadic AD cases and therefore, in our opinion, strengthen the hypothesis, which will be the focus of this review.
© 2006 Elsevier B.V. All rights reserved.Keywords: Mitotic insult; Oxidative stress; AβPP; Tau; Mitotic steady state; Oxidative steady state1. Introduction
The pathological presentation of Alzheimer disease (AD),
the leading cause of senile dementia, involves regionalized
neuronal dysfunction/death and an accumulation of intraneur-
onal and extracellular lesions termed neurofibrillary tangles
(NFT) and senile plaques, respectively [1]. To date, despite
intensive efforts, the mechanism(s) responsible for selective
neuronal death and dysfunction in AD remain unclear which has
greatly impacted the development of accurate animal and
cellular models and thereby retarded the development of
therapeutic modalities. Several independent hypotheses have
been proposed to link the pathological lesions and neuronal
cytopathology with, among others, apolipoprotein E genotype
[2,3]; hyperphosphorylation of cytoskeletal proteins [4],
oxidative stress [5], abnormal cell cycle re-entry [6,7],
inflammation [8] and amyloid-β (Aβ) metabolism [9]. How-
ever, not one of these theories alone is sufficient to explain the
diversity of biochemical and pathological abnormalities of AD
which involves a multitude of cellular and biochemical changes.
Furthermore, attempts to mimic the disease by a perturbation of
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doi:10.1016/j.bbadis.2006.10.014transgenic animals, do not result in the same spectrum of
pathological alterations. The most striking example being that
while Aβ plaques are deposited in some transgenic rodent
models overexpressing amyloid-β protein precursor (AβPP),
there is no neuronal loss [10]—a seminal feature of AD. The
relative modality of single-insult models to accurately reflect
disease pathogenesis led us to speculate that AD, like cancer,
may be the result of serial insults that alone are insufficient to
lead to disease and therefore proposed a “two-hit hypothesis”
stating that both oxidative stress and mitogenic dysregulation
are necessary and sufficient to cause the disease and suggested
that it may be a common mechanism for other neurodegenera-
tive diseases as well [11]. Two years have passed since we first
put forward this hypothesis and exciting developments in the
field confirm many of the predictions and therefore strengthen
the hypothesis. Obviously more work is still needed to continue
to test and define.
2. Oxidative stress and Alzheimer disease
What many of the theories of AD pathogenesis have failed to
incorporate is that AD is a disease of aging [12]. Importantly,
this holds true even in individuals with a genetic predisposition,
i.e., those individuals with an autosomal dominant inheritance
of AD or in individuals with Down's syndrome who develop
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100% of AD cases, whatever the genetic background. Since the
aging process is associated with an increase in the adventitious
production of oxygen-derived radicals, i.e., reactive oxygen
species (ROS), together with a concurrent decrease in the ability
to defend against such ROS, not surprisingly, studies over the
past 10 years have established oxidative stress and damage not
only in the lesions of AD but also in neurons at risk of death
[13–20]. In AD, in addition to this background level of ROS,
there are a number of additional contributory sources that are
thought to play an important role in the disease process: (1)
Excessive deposits of iron and/or copper catalyze the formation
of ˙OHU from H2O2 as well as the formation of advanced
glycation end products. (2) Activated microglia, such as those
that surround most senile plaques [21], are a source of NOU and
O2
− [22] which can react to form peroxynitrite, leaving
nitrotyrosine as an identifiable marker [19,23]. (3) Aβ itself
has been directly implicated in ROS formation through peptidyl
radicals [24–26]. (4) Advanced glycation end products in the
presence of transition metals (see above) can undergo redox
cycling with consequent ROS production [27,28]. Additionally,
advanced glycation end products and Aβ activate specific
receptors such as the receptor for advanced glycation end
products (RAGE) and the class A scavenger-receptor to increase
ROS production [29,30]. (5) Abnormalities in mitochondrial
metabolism, such as deficiencies in key enzyme function,
resulting in part from detection of the mitochondrial genome,
suggest the mitochondria may be the major and possible
initiating source of ROS [31]. (6) Abnormalities in proteasomal
function or protein degradation systems. An exact determina-
tion of the contribution of each source of oxidative stress is
complicated if for no other reason than that most sources have
positive feedback. Nonetheless, the overall result is damage
including advanced glycation end products [32], nitration
[19,23,33,34], lipid peroxidation adduction products [35–41]
as well as carbonyl-modified neurofilament protein and free
carbonyls [14,16,17,32,41,42] with the involvement extending
beyond the lesions to neurons not displaying obvious
degenerative change. Notably, the very earliest neuronal and
pathological changes characteristic of AD [43–46] suggest
oxidative stress as a very early contributor to the disease. This
early role is borne out by clinical management of oxidative
stress which appears to reduce the incidence and severity of AD
[47,48]. Indeed, oxidative damage marked by lipid peroxida-
tion, nitration, reactive carbonyls and nucleic acid oxidation is
increased in vulnerable neurons whether or not they contain
NFT [45,49] suggesting that increases in neuronal oxidative
damage must precede neurofibrillary pathology formation.
Moreover, a marked accumulation of oxidative active mod-
ification products, i.e., 8-hydroxyguanosine (8OHG) and
nitrotyrosine, in the cytoplasm of cerebral neurons from Down's
syndrome, who invariably develop AD symptoms in their teens
and twenties, temporally precedes amyloid-β deposition often
by decades [44,50]. That oxidative damage is the earliest event
preceding the formation of pathologies is also confirmed in AD
brains [45]. This is further supported by the findings on Tg2576
AβPP transgenic mice model in which oxidative stress precedesAβ deposition [46,51]. However, given that the field shifts
towards the notion that soluble Aβ oligomers rather than fibrils
may be the culprit, studies seriously assessing the temporal
relationship between oxidative stress and soluble Aβ oligomers
are obviously needed but appear to be technically challenging.
Nevertheless, recent studies found increased levels of isopros-
tane, a product of polyunsaturated fatty acid oxidation, in living
patients diagnosed with mild cognitive impairment (MCI), a
prodromal stage of AD and probable AD, suggesting that lipid
peroxidation is present at a very early stage, well before the end-
stage of the disease [52–54]. Along this line, individuals with
MCI or very mild AD show increased levels of various lipid
peroxidation and nucleic acid oxidation in postmortem brain
tissues, cerebrospinal fluid, plasma, urine and peripheral
leukocytes as well as decreased levels of plasma antioxidants
and total plasma antioxidant capacity [55–57]. Heme oxyge-
nase-1, a sensitive marker of oxidative stress, is also
upregulated in postmortem brains of AD and MCI [58].
3. Mitotic abnormalities and Alzheimer disease
The cell cycle is a highly regulated process to ensure a
homeostatic balance between cell proliferation and cell death in
the presence of appropriate environmental signals. In eukaryotic
cells, the cell cycle is typically divided into four phases: the S
phase of DNA replication and the M phase of mitosis, separated
by two gap phases called G1 and G2. Cyclin-dependent kinases
(CDK), together with cyclins, are the major regulators of cell
cycle progression and upon receiving external stimuli, cells up-
regulate CDKs and cyclins to orchestrate the numerous process
required for cell proliferation [59]. Any perturbation of these
regulators will result in the arrest of the cell cycle and/or cell
death.
Neurons in the adult CNS have classically been described as
being in a terminally differentiated state meaning that they no
longer return to the cell cycle. However, around 10 years ago, a
rather surprising finding was made, such that in AD, susceptible
cortical neurons display an activated cell cycle phenotype
including the ectopic presence of various cyclins, cyclin-
dependent kinases, and cyclin-dependent kinase inhibitors
[60–66]. Periodically, we see new markers of cell cycle entry
being associated with either neuronal pathology present in AD
or present in neurons that are vulnerable to changes that lead to
AD [67–74]. This evidence suggests that in AD, susceptible
neuronal populations, which are postmitotic and thus restricted
in their mitotic competence, actually exit G0 and re-enter the G1
phase of the cell cycle during the progression of AD and
therefore, helps cement the early and possibly irreversible fate
of these vulnerable neurons. In addition to the presence of cell
cycle phase dependent kinases, this “re-entrant” phenotype is
also supported by activation of selective signal transduction
pathways, transcriptional activation that results in cytoskeletal
changes such as tau phosphorylation, alterations in mitochon-
drial activity and DNA replication [75–80]. In this sense, AD
neurons resemble those normally seen only during development
neurogenesis, in mitotically active cells and in neoplastic cells.
In neoplasia, such ectopic mitogenicity is, by definition, due to a
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neurons of AD it is due to an emergence out of terminal
differentiation and attempted re-entry into the cell cycle.
However, as yet, there is no evidence suggesting a successful
nuclear division in AD implying that the neurons do not
complete mitosis (M-phase). In fact, terminally differentiated
neurons may lack the ability to complete the cell cycle such that
the mitotic alterations (i.e., re-activation of cell cycle machin-
ery) may contribute to neuronal death. Despite the consensus
that these vulnerable neurons re-enter cell cycle and no actual
mitosis occurs, it is unclear how far they go since G1, S and G2
phase markers are all reported [81]. Indeed, the characteristic
profile of cyclin-CDK activity in phase of the each cell cycle in
normal dividing cells is lost when these susceptible neurons
attempt to re-enter cell cycle which points to the highly
unorganized nature of the cell cycle in these neurons. For
example, Cdk4 and p16 are expressed concurrently in these
neurons which is not seen in normally dividing cells [64].
Another frequently encountered enigma is that most of these
cell cycle markers are re-expressed in cytoplasm rather than in
the nucleus where they act [61,68,69]. Although the conse-
quence of such a re-entrant phenotype is unclear, it is
conceivable that all these abnormalities point to an inadequate
or a failed control of cell cycle in these neurons that may
contribute to their eventual death in AD. Notably, like oxidative
stress, mitotic proteins are not exclusively associated with end
stage of neuropathology but rather with the very earliest
neuronal changes to occur in the disease [62,64,70,82]. Indeed
cell cycle markers occur prior to the appearance of gross
cytopathological changes [83] and the proximal nature of
mitotic events has been shown in pre-AD patients with MCI
which represents a prodromal stage of AD [73].
4. The two-hit hypothesis
It is evident that both oxidative stress and aberrant mitotic
signalling play early roles in the pathogenesis of AD, but their
temporal relationship to each other is unclear. Based on the
studies of oxidative stress signalling and mitotic signalling
pathways in vulnerable neuronal populations in AD, we
hypothesized that both oxidative stress and aberrant mitotic
stimuli can independently initiate, yet both are necessary to
propagate disease pathogenesis and progression, which was
termed as the “two-hit hypothesis” [11]. Importantly, there are
two major assumptions of this hypothesis: (1) the presence of a
steady state: after the process being initiated by one of these two
hits, neurons recruit permanent adaptive changes and enter a new
steady state that can last for decades where they still function
normally or at worse, in a slightly compromised fashion; (2) the
depletion of neuronal compensatory potential: the new steady
state requires great compensatory adaptations which likely
deplete much of the neuronal compensatory potential to fight
against insult (i.e., first hit), therefore, neurons at new steady
state are uniquely vulnerable to secondary insults that requires
additional compensatory changes in other pathways.
It appears that evidence supports the presence of “oxidative
steady state” and extensive compensatory adaptations whenneurons are subject to an oxidative injury. It is clear that
oxidative stress is a pervasive feature in AD at all stages [84,85].
Although high levels of acute oxidative stress would inflict
neuronal death such as those seen in cases of trauma and
ischemia, this type of oxidative damage is not the case in AD
and indeed neuronal pathology after brain trauma and ischemia
is significantly different from AD brain. What is striking is that
few neurons (less than 1/10,000 at any given time) exhibit signs
of apoptosis [86,87] as would be expected under conditions of
acute and high level of oxidative stress. Thus, oxidative
challenges in AD seemingly do not exceed oxidative defenses
otherwise rapid apoptotic death will result. In this event, it is
clear that relatively low concentrations of oxidants such as
hydrogen peroxide induce an adaptive response rather than cell
death [88–91]. Therefore, a uniquely chronic, tolerable
exposure of neurons to oxidative stress provides an explanation
for the low levels of neuronal apoptosis in AD [80,92–95].
Tolerable levels of oxidative stress provoke compensatory
changes that lead to a shift in neuronal homeostasis which is
initially reversible if the oxidative stress is acute. However, with
persistent oxidative stress such as seen in pre-AD and AD cases
which is significant as compared to age-matched controls, it is
not only likely, but essential that, after a certain threshold (in
terms of severity and chronicity of oxidative stress), the
majority of neurons recruit permanent adaptive changes but
still function normally or slightly compromised in a pro-oxidant
environment. In other words, neurons enter an oxidative steady
state. It is of interest to note that neurons bearing NFT, a
potential compensatory adaptation, demonstrate lower level of
oxidative damage and can survive for decades [96]. Similarly,
increased density of Aβ plaque deposition, also a likely
compensatory adaptation, is associated with decreased levels
of neuronal oxidative damage [44,45,97]. Although it is
debatable whether NFT-bearing neurons exist in an oxidative
steady state, obviously they develop extensive compensatory
adaptations involving transcriptional changes which likely
greatly limit their capability for further compensatory adapta-
tion in the face of additional insults. For example, some recent
studies suggested over 225 genes showing progressively
increased or decreased expression in AD NFT-bearing neurons
compared to AD non-NFT neurons or control non-NFT neurons
[98] and many proteins involved in oxidative stress are
implicated [99].
5. AβPP mutants cause neurons enter mitotic steady state
The two-hit hypothesis suggests that the reverse, mitotic
followed by oxidative insult, is also possible, in which case
neurons that have re-entered into what will become a futile
attempt at division (i.e., mitotic steady state), are more
vulnerable to changes in oxidative stress that requires further
adaptation. The presence of such mitotic steady state, implicat-
ing that neuronal cell cycle re-entry is necessary but not
sufficient to cause cell death in those postmitotic neurons
susceptible to AD, was quite a different view from a more
popular idea that initiation of cell cycle is sufficient to cause cell
death in postmitotic neurons as observed in a large number of
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vitro studies suggested that G1/S cell cycle blockers and
inhibitors of CDKs as well as dominant negative forms of Cdk4/
6 prevent neuronal death induced by various conditions such as
DNA damaging agents or Aβ [100–103]; Very recently, it was
demonstrated that adenoviral-mediated expression of c-myc and
ras oncogenes drives postmitotic primary cortical neurons into
the cell cycle followed by a steady decrease in the overall DNA
content and DNA condensation consistent with cell death which
provides a more direct link [104]. More importantly, when
SV40T antigen is expressed specifically in maturing Purkinje
cells in transgenic mice, the cells replicate their DNA but then
subsequently degenerate and die [105]. Similarly, the expres-
sion of SV40T antigen by the rhodopsin promoter causes cell
cycle reactivation and DNA synthesis followed by photorecep-
tor degeneration [106]. Widespread neuronal apoptosis also
occurs in the CNS of retinoblastoma (pRb)-deficient mice
[107–109]. However, given the widespread cell cycle markers
in most susceptible neurons in AD [60,61], as argued above, it is
impractical for all these cells to die acutely as found in these cell
culture or animal models. Therefore, it is more likely that these
cells achieve a more stable and near normal state and function
for relatively a long period of time which we termed “mitotic
steady state”. This is supported by very interesting findings in
pRb−/− chimeric mice in which the majority of pRb-deficient
cells survived and differentiated into neuronal fates despite an
obvious ectopic S-phase entry and accumulation of cells with 4n
DNA content [110]. Indeed, since there were massive neuronal
apoptosis in pRb-deficient mice, this rather unexpected finding
in pRb−/− chimeric mice also confirms that other factors (or so-
called non-cell-autonomous factors) can determine the final
outcome even in the presence of genetic defects directly linked
to cell cycle control which has important implications in
familial AD. More importantly, conditional deletion of Rb only
in the CNS caused cell cycle abnormalities without apoptosis in
the CNS and it turned out that hypoxia, which presumably can
cause oxidative stress, may be an essential additional insult that
is required to induce massive neuronal loss in pRb-deficient
mice, therefore, exemplifying a two-hit neuronal degeneration
in a mouse model [111].
Mutations in at least three genes, the AβPP and the two
presenilin genes, PS1 and PS2, are associated with early-onset
AD [112]. We suggested that AβPP, PS1 and PS2 may share a
common function in cell cycle control which may be key to the
two-hit hypothesis since neurons bearing these mutations may
enter a mitotic steady state, depleting their compensatory
potential, which renders them more vulnerable to additional
insults [11]. The presence of such a mitotic steady state is very
likely as discussed above in the case of pRb−/− chimeric mice
[110]. Indeed recent development in the field appears to support
our proposal of the presence of mitotic steady state in AβPP
mutant bearing neurons. Both ectopic expression of cell cycle
markers and DNA replication were reported in three different
transgenic models of AD carrying AβPP Swedish mutants—
R1.40, Tg2576 or Tg2576/PS1 and APP23 [74]. Neuronal cell
cycle re-entry in these mice precedes amyloid deposits by
several months and occurs in an anatomical pattern thatrecapitulates the selective neuronal vulnerability observed in
AD. Since none of these mouse models develops significant
neuronal loss and they only display mild behavioral abnormal-
ities suggesting that these mouse neurons, despite re-entering
cell cycle as early as 6 month of age, maintain a near normal
state, these findings not only confirm our suggestion that cell
cycle re-entry is not sufficient for neuronal death, but also
provide an actual example of the presence of mitotic steady state
in an AD-relevant model. However, before we can whole-
heartedly embrace this notion, it must be noted that there is still
controversy regarding AβPP mutant causing cell cycle abnorm-
alities since an earlier studywithAPP23mice failed to detect any
neuronal cell cycle abnormalities [113] and the reason of such
discrepancy is unclear. Recent studies utilizing powerful genetic
tools such asDrosophilamodels convincingly demonstrated tau
defects cause neuronal cell cycle activation [114] and the
availability of similar Drosophila model overexpressing mutant
AβPP [115] may help to answer this important question and
shed new light on the potential mechanism(s). Nevertheless,
multiple recent studies demonstrate neurons bearing AβPP
mutations show extensive alterations in gene expression profiles
including those involved in nucleotide and protein synthesis,
neurotransmitter metabolism, neuronal outgrowth and energy
metabolism [116–118], underlying the notion of great compen-
satory adaptations in these neurons which may render themmore
vulnerable to additional insults. Bearing this in mind, one may
then argue why there is no obvious neuronal death in AβPP
mutant SOD2 heterozygous knockout mice [119,120] which
presumably have higher oxidative stress along with AβPP
mutant. One potential explanation is that neurons bearing these
two genetic defects from the very beginning when they possess
greatest compensatory potential are very different from those
50–60 years old neurons with stereotyped adaptations facing
demands for additional adaptation. The more relevant situation
is to subject old AβPP transgenic mice to oxidative stress and
indeed these mice demonstrate greater vulnerability to ischemia
[121], traumatic brain injury [122] and some physiological
stressors [123].
6. Tau and two-hit hypothesis
Tau, as AβPP, is another major protein implicated in AD.
Maybe not coincidentally, a recent breakthrough in this field
was the demonstration that tau alterations, also like AβPP
mutations, lead to cell cycle abnormalities in various animal
models. The elegant genetic studies using a fly tauopathy model
convincingly demonstrated that tau alterations are causally
linked to cell cycle re-entry [114]. Most importantly, this study
demonstrated that both wild type and mutant tau can cause cell
cycle re-entry which depends upon tau hyperphosphorylation.
Complementing these exciting findings in fly model, tau
alterations also induce abnormal cell cycle alterations in
mouse models. In transgenic mice expressing human P301S
tau protein, despite a lack of activation of various cell cycle
activators, there is increased neuronal expression of p21Cip1
and p27Kip1 in spinal cord and cortex and most importantly,
just like in AD, they were mislocalized to cytoplasm compared
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More clearly, we had found profound nuclear PCNA immunor-
eactivity in another tauopathy mouse model, JNP301L mice,
confirming that disease-causing tau mutations can cause cell
cycle abnormalities in mammalians (Fig. 1A–D). Perhaps more
importantly in relation to sporadic AD, aged tau mice, which
express nonmutant human tau isoforms but no mouse tau
isoforms and develop tau pathology more faithful to AD in
terms of age-dependence and distribution [125], display ectopic
expression of various cell cycle regulator proteins and DNA
synthesis in brain regions where cell death is extensive and most
affected in AD, supporting that nonmutant tau also can cause
cell cycle re-entry in mammalians [126]. The finding that tau
alterations, especially the overexpression of wild type tau, can
cause cell cycle re-entry in neuronal populations susceptible to
AD has profound implications in relation to two-hit hypothesisFig. 1. PCNA is found at significantly higher levels in neuronal nuclei in both the hind
compared with 8-month-old wildtype in both the hindbrain (B) and cortex (D). p38 (
month-old JNPL301L brain (E). Using double label immunocytochemistry, signific
neuronal cell bodies (F). Scale bar A–D=50 μm; E–F=50 μm.as it applies to sporadic AD and tauopathies since these diseases
are associated with abnormal neuronal accumulation of wild
type tau as well as hyperphosphorylated tau. Although it is
easier to understand in familial AD, as we originally suggested
in two-hit hypothesis, even in sporadic AD, cases due to mitotic
followed by oxidative insult are also possible. That tau
alteration (i.e., accumulation and/or hyperphosphorylation)
causes cell cycle abnormality may be one of the major
mechanisms how such sporadic cases with mitotic steady
state followed by additional oxidative hit arise. Indeed, a recent
paper describing the presence of several subgroups of AD
suggesting different initiation pathways including alterations in
tau or ubiquitin (proteasomal dysfunction or oxidative stress?)
[127] appears to support this idea. Interestingly, this study also
suggested that age effect significantly affects tau which implies
that tau alteration-induced cell cycle re-entry is also agebrain (A) and cortex (C) of 8-month-old JNP301L tauopathy mouse model when
antibody from Stressgen) is readily detectable in many neuronal cell bodies in 8-
ant overlap of both p38 (brown) with phosphorylated tau (blue) is seen in the
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those AβPP transgenic mice, these animal models with tau
alterations all develop neuronal death [114,126,128,129],
seemingly suggesting that tau-induced cell cycle re-entry is
sufficient to induce cell death without the necessity of an
additional hit. Before reaching such conclusion, one should bear
in mind the Rb−/− mouse story [110,111] to more carefully
search for the true reason of neuronal death in these models.
Actually, at least in JNP301L tauopathy mouse model, impaired
mitochondrial respiration and ATP synthesis together with
higher levels of ROS and modified lipid peroxidation levels
were noted in aged transgenic mice [130]. Similarly, it was
previously reported that the ERK and JNK pathways are
activated [131], and we further demonstrated that p38 is also
altered in this model (Fig. 1E–F), which makes it very similar to
AD where all these three MAPK pathways are activated [80].
Therefore, these findings implicate that not only cell cycle re-
entry but also oxidative stress may contribute to the eventual
neuronal demise in this model.
7. Conclusion
In summary, from the perspective of two-hit hypothesis,
recent developments in the field not only provide strong
evidence supporting the presence of mitotic steady state in
neurons bearing genetic defects [74,110,111], but also shed
light on mechanisms regarding how neurons may enter a
mitotic steady state in sporadic cases such as through tau
alterations [114,124,126]. The presence of subgroups of AD
suggesting several different initiation pathways in the
pathogenesis of this disease [127] may also fit well with
this hypothesis. Equally important, the fact that neurodegen-
eration observed in pRb-deficient mice [107–109] is likely
due to both pRb-deficiency induced cell cycle re-entry and
hypoxia-induced stress [110,111] underscores our original
hypothesis that the two-hit model may also have more
general implications in other neurodegenerative diseases.
Depending on the specific brain regions involved and other
variations, the hit may not necessarily be oxidative stress or
cell cycle abnormalities. As long as it requires compensatory
adaptations of different pathways, the first hit makes neurons
vulnerable while the second hit triggers the whole degen-
erative process.References
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